We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A Luxembourg-based nonprofit set up by European pharma groups is one step closer to launching a counterfeit drug repository system, having finalized contracts with three software firms to help implement the system. Read More
AstraZeneca has sold global rights, excluding the U.S., to its Entocort gastroenterology drug to Tillotts Pharma for $215 million, as it focuses on cancer and diabetes therapies. Read More
Increasing data is driving collaboration among drugmakers, insurers, health systems and technology firms to deliver cost-effective and improved treatments to patients, a just-released PwC report concludes. Read More
A Delaware state judge dismissed with prejudice a decade-old lawsuit filed by six New York Teamsters organizations against AstraZeneca alleging consumer fraud over marketing of the heartburn drug Nexium, saying the purchasers had no evidence they’d been harmed. Read More
Teva said Wednesday that it has launched a generic version of Janssen Pharmaceutical’s migraine drug Axert in the U.S., following receipt of FDA approval. Read More
A former Warner Chilcott district sales manager pleaded guilty Tuesday to conspiring to deceive Medicare and private health insurers so they would pay for the firm’s osteoporosis drugs, Actonel and Atelvia. Read More
Amphastar is facing increasing pressure to cut the high cost of naloxone, this time in a letter from Rep. Elijah Cummings to Maryland officials urging them to negotiate a lower price for the opioid overdose reversal drug. Read More
The second former Gallant Pharma International employee in as many days has been barred by the FDA from doing business in the U.S., after she was convicted of a felony for selling counterfeit drugs. Read More